News Release(2009)
2009
-
November 25, 2009
Approval of Glufast®, a rapid-acting insulin secretagogue in the China
-
November 24, 2009
A Positive Opinion from European Regulatory Authorities for SILODOSIN (Brand Name in Japan: Urief®) for The Treatment of Dysuria Associated with Benign Prostatic Hyperplasia
-
September 9, 2009
SILODOSIN (Brand Name in Japan: Urief®), a Treatment for Dysuria Associated with Benign Prostatic Hyperplasia, to be Launched in South Korea
-
July 3, 2009
Discontinuation of the development of "Remogliflozin" by GlaxoSmithKline
-
April 8, 2009
SILODOSIN Launched (Brand Name in Japan: Urief®) in the US
-
April 2, 2009
Kissei and Eisai Sign License Agreement for Urief®, A Treatment for Dysuria Associated with Benign Prostatic Hyperplasia for ASEAN Countries, India, and Sri Lanka
-
February 24, 2009
Approval of an Additional Indication of Combination Therapy of Glufast® and Insulin Sensitizer in Japan
-
February 4, 2009
Kissei and Daiichi Sankyo to Launch Urief® Tablet, a Treatment for Dysuria Associated with Benign Prostatic Hyperplasia
